Perceptive Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Perceptive Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$41M	Hold	170,000	–	–	0.61%	35
2026 Q1	$32.1M	Hold	170,000	–	–	0.63%	37
2025 Q4	$28.9M	Buy	+170,000	New	+$26.1M	0.52%	48
2017 Q3	–	Sell	-85,572	Closed	-$13.3M	–	147
2017 Q2	$13.3M	Buy	85,572 +55,572	+185%	+$8.5M	0.67%	43
2017 Q1	$4.35M	Sell	30,000 -22,000	-42%	-$2.87M	0.25%	65
2016 Q4	$5.67M	Buy	+52,000	New	+$5.79M	0.4%	56

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Perceptive Advisors's JAZZ Position: Q2 2026 in Review

Perceptive Advisors held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 170,000 shares worth $41M. The position accounts for 0.61% of the portfolio, ranked #35.

Perceptive Advisors first reported a position in JAZZ in Q4 2016 and has held it in 6 quarters since. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Perceptive Advisors held 170,000 shares of Jazz Pharmaceuticals worth $41M as of Q2 2026.
Perceptive Advisors left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
Jazz Pharmaceuticals made up 0.61% of Perceptive Advisors's portfolio in Q2 2026, its #35 holding.
Perceptive Advisors first reported a position in Jazz Pharmaceuticals in Q4 2016 and has held it in 6 quarters since.
641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.